Proxy Materials

Aclaris Therapeutics, Inc. Filed 2022-04-21 Acc 0001558370-22-005683

Documents 1

2023-04-20 DEFA14A Proxy Materials
2022-04-25 4 President and CEO sold 70,000 shares at an average $15.15 ($1,060,701)
2022-04-25 SC 13G Amended Statement of Ownership
2022-04-21 DEFA14A Proxy Materials
2022-04-21 DEF 14A Proxy Statement
2022-04-20 4 Chief Scientific Officer sold 30,000 shares at $16.28 ($488,298)
2021-04-22 DEFA14A Proxy Materials

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

Loading tmb-20220602xdefa14a.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…